These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 11393735

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
    Fuchs P, Haefeli WE, Ledermann HR, Wenk M.
    Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
    [Abstract] [Full Text] [Related]

  • 3. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK.
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
    Krul C, Hageman G.
    J Chromatogr B Biomed Sci Appl; 1998 May 08; 709(1):27-34. PubMed ID: 9653923
    [Abstract] [Full Text] [Related]

  • 7. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
    Rasmussen BB, Brøsen K.
    Ther Drug Monit; 1996 Jun 08; 18(3):254-62. PubMed ID: 8738764
    [Abstract] [Full Text] [Related]

  • 8. Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
    Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, Sörgel F, Fuhr U.
    Eur J Clin Pharmacol; 2009 Apr 08; 65(4):411-7. PubMed ID: 19082994
    [Abstract] [Full Text] [Related]

  • 9. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans.
    Tsutsumi K, Kotegawa T, Matsuki S, Tanaka Y, Ishii Y, Kodama Y, Kuranari M, Miyakawa I, Nakano S.
    Clin Pharmacol Ther; 2001 Aug 08; 70(2):121-5. PubMed ID: 11503005
    [Abstract] [Full Text] [Related]

  • 10. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
    Hakooz NM.
    Curr Drug Metab; 2009 May 08; 10(4):329-38. PubMed ID: 19519341
    [Abstract] [Full Text] [Related]

  • 11. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
    Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J, Wolf H, Smith G, Cascorbi I, Sörgel F, Fuhr U.
    Eur J Clin Pharmacol; 2004 Mar 08; 60(1):17-21. PubMed ID: 14747882
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
    Chen Y, Xiao P, Ou-Yang DS, Fan L, Guo D, Wang YN, Han Y, Tu JH, Zhou G, Huang YF, Zhou HH.
    Clin Exp Pharmacol Physiol; 2009 Aug 08; 36(8):828-33. PubMed ID: 19215233
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acetylator phenotyping via analysis of four caffeine metabolites in human urine by micellar electrokinetic capillary chromatography with multiwavelength detection.
    Guo R, Thormann W.
    Electrophoresis; 1993 Aug 08; 14(5-6):547-53. PubMed ID: 8354241
    [Abstract] [Full Text] [Related]

  • 15. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
    Kashuba AD, Bertino JS, Kearns GL, Leeder JS, James AW, Gotschall R, Nafziger AN.
    Clin Pharmacol Ther; 1998 May 08; 63(5):540-51. PubMed ID: 9630827
    [Abstract] [Full Text] [Related]

  • 16. Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry.
    Schneider H, Ma L, Glatt H.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jun 15; 789(2):227-37. PubMed ID: 12742114
    [Abstract] [Full Text] [Related]

  • 17. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
    Vrtic F, Haefeli WE, Drewe J, Krähenbühl S, Wenk M.
    Br J Clin Pharmacol; 2003 Feb 15; 55(2):191-8. PubMed ID: 12580991
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
    Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF.
    Pharmacogenetics; 1992 Jun 15; 2(3):116-27. PubMed ID: 1306111
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.